PARIS–(BUSINESS WIRE)–The first edition of the HealthTech Investor Days (HTID)
will take place in Paris on June 24th and 25th
2019. This new forum will help 100 late-stage European HealthTech
companies secure the development of new medicines and therapeutic
solutions. Launched by France Biotech with the support of the European
health innovation ecosystem, HTID will facilitate one-on-one meetings
between European health entrepreneurs, international investors and major
pharmaceutical companies. The two-day event will also feature a dozen
plenary meetings on global issues in health innovation.
Europe is a major player in medicine of the future thanks to the
excellence of its scientific research and the growing number of
innovative HealthTech companies. It is home to 3,000 biotechs and 27,000
medtechs according to European sources EuropaBio and Medtech Europe.
Europe’s potential in health innovation is hampered by the structural
weakness in funding for the sector which requires large capital
investments and long-term financing. The development of a new drug from
benchside research to the market takes ten to fifteen years on average.
For medical devices, the development process usually lasts three to
seven years.
In the past two years, investment in HealthTech companies around the
world has been rising sharply. However, Europe has benefited only
partially from this trend. In 2017, the global amount of funds raised in
the HealthTech sector in Europe (via venture capital and IPOs) reached €
6.2 billion (source: EY). This represents less than a third of the funds
raised in the United States alone during the same period (€ 19.8
billion). In 2018, the European investment deficit increased further
with a total of 5.8 billion euros funds raised (down 6.5% compared to
2017). Meanwhile, 27 billion euros (+ 36.3%) were invested in HealthTech
in the United States. This means that American health innovation now
attracts five times more investment than European health innovation.
HTID is a response to this crucial need for financing and support by the
industry. The event will take place on an annual basis to help overcome
this lack of investment in the European HealthTech sector.
Contacts
Press contacts:
ALIZE RP:
Caroline Carmagnol
francebiotech@alizerp.com